Navigation Links
InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
Date:11/5/2009

r than $22.7 million in the first nine months of 2008, primarily reflecting costs related to preparation for the potential commercialization of pirfenidone, which is subject to regulatory approvals. Expenses in the first nine months of 2009 included a milestone payment of $13.5 million for pirfenidone made to Marnac/KDL in accordance with the pirfenidone purchase agreement and InterMune's decision to submit NDA and MAA filings for pirfenidone.

On January 1, 2009, the company adopted guidance in the Debt Topic of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), formerly FASB Staff Position APB 14-1, "Accounting for Convertible Debt Instruments That May Be Settled In Cash Upon Conversion (Including Partial Cash Settlement)," and recorded additional interest expense for the third quarter of 2009 of $1.0 million and $3.7 million for the first nine months of 2009. This guidance requires retrospective application upon adoption; therefore, net losses attributable to InterMune for the third quarter and first nine months of 2008 have been adjusted from those which were previously reported to reflect additional interest expense of $1.5 million and $6.0 million, respectively.

Clinical Development Highlights - Third Quarter and Recent Events

Pirfenidone:

  • On November 4, InterMune announced that it had submitted an electronic NDA with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with IPF. Pirfenidone has been granted both "Fast Track" and Orphan Drug designations by the FDA.
  • An oral presentation focused on the safety profile of pirfenidone was presented at the European Respiratory Society (ERS) Annual Congress in Vienna, Austria on September 14. Safety data from four clinical studies -- CAPACITY 1, CAPACITY 2, RECAP and a long-term open-label study -- showed that treatment with pirfenidone was
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
Breaking Medicine Technology:Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Study ... Finds -, PRINCETON, ... of,vesicoureteral reflux (VUR) in children, reduced the incidence of recurrent,urinary tract infections ... in the July issue of the Journal of,Laparoendoscopic & Advanced Surgical Techniques. ...
... Online on Aug. 5 in Nature Journal, CLEVELAND, ... region within high density lipoprotein (HDL), the major,carrier of ... inhibiting the body,s ability to fight cholesterol buildup. ... M.D., Ph.D., Head of,the Section of Preventive Cardiology and ...
Cached Medicine Technology:DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 2DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 3DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux 4Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 2Researchers at Cleveland Clinic Identify Site of 'Dysfunction' in HDL, Carrier of Good Cholesterol 3
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Nov. 7 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that it will release its financial results for,the quarter ... after,the close of the U.S. financial markets. CryoCor ... at 5:00 p.m. ET /,2:00 p.m. PT on November ...
... With Business Objectives, Watson ... Survey Finds, WASHINGTON, Nov. 7 With continuing ... offer financial,incentives to reward workers who adopt healthy lifestyles, ... global consulting firm, and the,National Business Group on Health, ...
... 7 A cholesterol-lowering drug appears to disrupt sleep ... Heart Associations Scientific Sessions 2007. , The findings are ... and may have adverse health consequences, such as promoting ... lead author of the study and an associate professor ...
... Nov. 7 Exposing estrogen-sensitive breast cancer cells to ... sewer and industrial waste causes the cells to multiply, ... at the annual meeting of the American Public Health ... will be presented at a special session on Contaminants ...
... Director, Campaign for,Tobacco-Free Kids, WASHINGTON, Nov. 7 ... Philip Morris and R.J. Reynolds tobacco companies have,again ... by defeating a,ballot initiative to increase Oregon,s cigarette ... companies will profit by selling more cigarettes,while Oregonians ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... Operating Officer, will present at the JMP Securities,Healthcare ... 2007 at 2:30 p.m.,Eastern Time. To access ... visit the Investor Relations section of Genomic Health,s,website ...
Cached Medicine News:Health News:CryoCor Announces Web cast and Conference Call of Third Quarter 2007 Results 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 2Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 3Health News:More Employers to Offer Workers Financial Incentives for Healthy Behavior 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2Health News:Extracts of catfish caught in polluted waters cause breast cancer cells to multiply 2Health News:Tobacco Industry Puts Profits Before Kids in Defeating Oregon Ballot Initiative 2Health News:Genomic Health to Present at JMP Securities Healthcare Focus Conference 2
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. High volume/low pressure cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. X-ray opaque line. Graduated. Single use. S...
Tube for Left Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Graduat...
Medicine Products: